恒瑞医药港股上市首日盘中涨超29%，A500ETF基金（512050）飘红，机构：中国创新药出海的全球竞争优势正在凸显

Group 1 - A-shares' three major indices turned positive, with the pharmaceutical sector showing overall positive sentiment on May 23 [1] - A500 ETF (512050) rose by 0.21% with a trading volume exceeding 1.1 billion yuan and a turnover rate over 7% [1] - Leading pharmaceutical stocks such as Tigermed, Kelun Pharmaceutical, Betta Pharmaceuticals, and CR Medical collectively strengthened, with Tigermed rising over 6% [1] Group 2 - China's innovative pharmaceutical companies are increasingly demonstrating global competitive advantages, particularly in overseas License-out transactions [2] - The emergence of the NewCo model has helped original pharmaceutical companies address challenges related to financing, monetization, and R&D risks [2] - Recent policy adjustments, including optimization of centralized procurement rules and increased support for innovative drugs, signal a favorable regulatory environment for the industry [2]